SCHEMBL6803303

SCHEMBL6803303

CC(C)c1cccc(C(C)C)c1NC(=O)N(Cc1ccccc1)CC1(c2nnnn2C)CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
UBE2M P61081 1/20 0.41
DCUN1D1 Q96GG9 1/20 0.41
SOAT2 O75908 2/20 0.39
SOAT1 P35610 2/20 0.39
ACAT1 P24752 1/20 0.39
NMBR P28336 1/20 0.37
PTGES O14684 4/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9765050 0.82 SOAT1 (0.51) UBE2MDCUN1D1SOAT2SOAT1ACAT1
SCHEMBL6803622 0.82 NMBR (0.45) UBE2MDCUN1D1SOAT2SOAT1ACAT1
SCHEMBL6805340 0.78 NMBR (0.48) UBE2MDCUN1D1SOAT2SOAT1ACAT1
SCHEMBL6808919 0.77 SOAT1 (0.50) UBE2MDCUN1D1SOAT2SOAT1ACAT1
SCHEMBL6802078 0.77 SOAT2 (0.40) UBE2MDCUN1D1SOAT2SOAT1ACAT1
SCHEMBL6182575 0.76 SOAT1 (0.42) UBE2MDCUN1D1SOAT2SOAT1ACAT1
SCHEMBL6186309 0.75 NMBR (0.51) SOAT2SOAT1ACAT1NMBR
SCHEMBL6218992 0.75 NMBR (0.46) UBE2MDCUN1D1SOAT2SOAT1ACAT1
SCHEMBL6184387 0.75 SOAT1 (0.38) UBE2MDCUN1D1SOAT2SOAT1ACAT1
SCHEMBL11143056 0.74 ALDH1A1 (0.58) UBE2MDCUN1D1SOAT2SOAT1PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063643-A1 Bombesin antagonists PFIZER INC. 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063643-A1 Bombesin antagonists BRS3, NPSR1, GNRHR UBE2M 3897/4885DCUN1D1 2124/4885SOAT2 3379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.